Stirling Announces:
• Q1 Progress Summary
• Strategic Review
• Proposed TeleMedCare Spinouts
• Placement Finalisation
Healthcare group, Stirling Products Limited
(ASX:STI) is pleased to advise and update the market as follows:
Q1 Progress Summary:
Following the completion of the recent placement of shares the Company is moving ahead on a number of initiatives including:
Stirling Health:
Inventory has been purchased and committed to the manufacture and delivery of the Kidney Vital™ product and is scheduled for launch in Australian pharmacies next month. Further the Company’s distribution of 3M’s Futuro™ and Nexcare™ products has been successfully integrated within the Stirling Health division and the market presence of these product ranges are already gaining in-store visibility. Rose-Hip Vital will no longer be represented and the Company is to replace this product with a specialised designer product in the near future. For further details on progress and future products at: www.stirlinghealth.com.au
For further information, please download the PDF below.
